Stockscreener 앱 받기
0.2642
3.65%
0.0093
시장 영업 전:
.26
-0.0042
-1.59%
Cue Biopharma Inc 주식(CUE)의 최신 뉴스
Cue Biopharma Inc stock faces key test amid biotech volatility and pipeline progress - AD HOC NEWS
Cue Biopharma (CUE) Projected to Post Earnings on Monday - Defense World
Published on: 2026-03-21 13:01:47 - baoquankhu1.vn
Buyout Rumor: What chart patterns are forming on Cue Biopharma IncShare Buyback & Community Consensus Picks - baoquankhu1.vn
Certain Stock Incentive Plan of Cue Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 20-MAR-2026. - marketscreener.com
Certain Common Stock of Cue Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 20-MAR-2026. - marketscreener.com
Loss Report: Can Cue Biopharma Inc outperform in the next rallyIndex Update & Verified Momentum Stock Alerts - baoquankhu1.vn
Cue Biopharma (NASDAQ: CUE) files $300M shelf registration, $12.7M ATM via Jefferies - Stock Titan
Cue Biopharma 2024 Annual Report – Clinical-Stage Immunotherapy Pipeline, Regulatory Strategy, and Collaboration Highlights - Minichart
CUE SEC FilingsCue Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Stock Report: Whats the RSI of Cue Biopharma Inc stockEarnings Growth Report & Smart Money Movement Alerts - baoquankhu1.vn
Cue Biopharma earnings beat by $0.10, revenue topped estimates - Investing.com Canada
Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - Bitget
Cue Biopharma issues quarterly and annual earnings update - Traders Union
Cue Biopharma : Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - marketscreener.com
Reverse split on agenda as Cue Biopharma (CUE) plans 2026 virtual meeting - Stock Titan
Cue Biopharma, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Cue Biopharma (CUE) posts 2025 results and $15M ImmunoScape pact - Stock Titan
Cue Biopharma (CUE) pivots to autoimmune focus amid going concern risk - Stock Titan
Cue Biopharma, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Cue Biopharma (CUE) price target decreased by 20.00% to 4.08 - MSN
Published on: 2026-03-13 09:51:08 - baoquankhu1.vn
Cue Biopharma (CUE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Cue Biopharma to present new in vitro data for CUE-401 - TipRanks
Cue Biopharma (CUE) Unveils Promising CUE-401 Data at Global Con - GuruFocus
Cue Biopharma unveils in vitro data for CUE-401 in autoimmune disease research - Traders Union
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026 - The Manila Times
Bull Run: Can Cue Biopharma Inc disrupt its industryWeekly Profit Recap & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Cue Biopharma (NASDAQ: CUE) to vote on 1-for-30–1-for-50 reverse split - Stock Titan
CUE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Update Recap: Can Cue Biopharma Inc disrupt its industryPortfolio Update Report & Fast Exit/Entry Strategy Plans - baoquankhu1.vn
Momentum Shift: Whats the MACD signal for OSR Holdings Inc Equity WarrantBull Run & Long-Term Safe Investment Ideas - baoquankhu1.vn
Stock Market Recap: Will Cue Biopharma Inc benefit from geopolitical trendsJuly 2025 Outlook & AI Powered Market Trend Analysis - baoquankhu1.vn
CUE Should I Buy - Intellectia AI
Cue Biopharma Sets 2026 Annual Meeting, Proposal Deadlines - TipRanks
Cue Biopharma sets April 13, 2026 annual meeting; February 28 deadline for shareholder proposals - TradingView
Cue’s CUE-401 well tolerated in mouse and NHP studies - BioWorld MedTech
Aug Technicals: Can Cue Biopharma Inc outperform in the next rallyJuly 2025 Levels & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Analyzing Cue Biopharma (NASDAQ:CUE) & Aardvark Therapeutics (NASDAQ:AARD) - Defense World
Autoimmune drug candidate CUE-401 passes early safety tests in animals - Stock Titan
Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases - Bitget
Can Cue Biopharma Inc. outperform in the next rally2025 Earnings Surprises & Growth Focused Entry Point Reports - mfd.ru
Cue Biopharma Names Lucinda Warren Chief Financial Officer - The Globe and Mail
How Cue Biopharma Inc. stock performs in rising dollar environmentWeekly Gains Report & Daily Risk Controlled Trade Plans - mfd.ru
Cue Biopharma appoints industry veteran Lucinda Warren as chief financial and business officer - marketscreener.com
Cue Biopharma (CUE) Appoints New Chief Financial and Business Of - GuruFocus
Cue Biopharma, Inc. Appoints Lucinda Warren as Chief Financial Officer, Effective February 9, 2026 - marketscreener.com
Cue Biopharma Names Lucinda Warren Chief Financial And Business Officer - Nasdaq
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer - Bitget
Cue Biopharma Appoints Lucinda Warren as Chief Financial and Business Officer - TradingView
Is Cue Biopharma Inc. stock attractive after correctionTreasury Yields & Short-Term High Return Ideas - mfd.ru
How Cue Biopharma Inc. stock reacts to job market dataInflation Watch & Proven Capital Preservation Tips - mfd.ru
Can Cue Biopharma Inc outperform in the next rallyJuly 2025 Chart Watch & Daily Stock Momentum Reports - baoquankhu1.vn
What’s the RSI of Cue Biopharma Inc. stockQuarterly Growth Report & Reliable Breakout Forecasts - mfd.ru
Is Cue Biopharma Inc. stock forming a triangle pattern2025 Market WrapUp & AI Driven Stock Movement Reports - mfd.ru
Volatility Watch: Is Cue Biopharma Inc forming a bullish divergence2025 Price Targets & Weekly High Potential Stock Alerts - baoquankhu1.vn
CUE Stock Price, Forecast & Analysis | CUE BIOPHARMA INC (NASDAQ:CUE) - Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Biotech Stocks Surge After Hours: IO Biotech Jumps 19%, Cue Biopharma And Cabaletta Bio Follow - Nasdaq
1.82%
자본화:
|
볼륨(24시간):